Please login to the form below

Not currently logged in
Email:
Password:

Amylin and Takeda discontinue obesity drug

Amylin Pharmaceuticals and Takeda Pharmaceutical Company discontinue pramlintide/metreleptin combined obesity treatment following a commercial reassessment

Amylin Pharmaceuticals and Takeda Pharmaceutical Company announced their decision to discontinue the development of pramlintide/metreleptin, a combination therapy for the treatment of obesity. 

This decision was reached after a “commercial reassessment” of the programme. This assessment took into account various factors including a revised development plan and the evolving dynamics within the obesity therapeutic area.

The drug comprised of pramlintide, an analogue of the natural hormone amylin, and metreleptin, an analogue of the natural hormone leptin. At the time of discontinuation, the drug was in its phase II stage, where it was an injection formula taken twice a day. 

Despite the discontinuation, Amylin and Takeda will continue to work together, and will continue to investigate the antibody-related laboratory finding with metreleptin treatment. Neither of the companies are expecting to revise the latest financial guide for their respective 2011 year. 

5th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...
How Helpful are Simple Health Messages?
...

Infographics